2023-508525-27-00招募中4 期
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with coronary artery disease and preDiabetES. A randomised clinical trial (CASCADES)
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2024年3月8日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- The impact of GLP-1 analogue treatment on the progression of coronary artery disease (expressed as a change in the % change in the volume of non-calcified atherosclerotic plaque in CT assessed by coronary CT) in relation to routine treatment (intention-to-treat);
研究概览
简要总结
To compare anti-atherosclerotic efficacy of treatment with oral GLP-1 agonist (semaglutide) vs SGLT-2 inhibitor (dapagliflozin), as compared to metformin, atop optimal dietand lifestyle modification-based therapy in patients with coronary artery disease (CAD) and prediabetes. The diagnosis of CAD will be defined as coronary atherosclerosis confirmed in contrast coronary computed tomography angiography (CCTA). The primary outcome is the effect of treatment to the coronary plaque progression/regression assessed in CCTA over the observation time of 24 months.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Diagnosed coronary artery disease (coronary artery stenosis of at least 20% with a reference diameter of >2.5 mm detected in a coronary CT scan or after percutaneous coronary revascularization)
- •Core CT scan performed <3 months after inclusion in the study, of at least good quality
- •Prediabetes defined as fasting blood glucose 100-125 mg% or Hba1c 5.70 6.49% (measurement documented during the screening/randomization visit or within 30 days before the screening/randomization visit) or a documented positive result of the oral stress test glucose (fasting blood glucose 100-125 mg% and 140-199 mg% 2 hours after an oral load of 75 g of glucose) performed within 30 days before the screening/randomization visit
- •Stable treatment and control of cardiovascular risk factors, including dietary and lifestyle management, for at least 4 weeks.
- •Willingness and ability to provide informed consent for participation in the study.
- •Capability and willingness, in the opinion of the investigator, to comply with all study requirements
排除标准
- •Severe valvular disease
- •Severe diseases of the musculoskeletal system requiring specific rehabilitation recommendations
- •Decompensated heart failure
- •Lack of consent to participate in the study
- •Severe arrhythmia/unexplained loss of consciousness
- •Other contraindications to physical exercise
- •Presence of an artificial valve, cardiac pacing system or other implantable device (e.g. cardioverter-defibrillator)
- •Use of glucose-lowering medications other than metformin
- •Use of weight loss medications
- •Condition after bariatric surgery
- •Diagnosed liver disease or ALT, AST greater than three times the upper limit of normal at the screening visit
- •History of pancreatitis or active pancreatitis
- •Decompensated hyperthyroidism
- •History of anaphylactic shock after administration of iodine contrast
- •Chronic kidney disease (GFR <60 ml/min/1.73 m2)
- •Participation in another clinical trial
- •Medullary thyroid cancer
- •Pancreatic cancer
- •Body mass index (BMI) >40 kg/m2
- •A clinical condition requiring surgical treatment of coronary artery disease
- •Pregnancy/lactation
- •Other known contraindications to treatment with metformin, dapagliflozin or semaglutide
- •Condition after coronary artery bypass surgery
- •Diagnosed diabetes or Hba1c>6.5 mg% at the time of screening/randomization visit
- •Other serious illnesses requiring planned hospital treatment during the examination
结局指标
主要结局
The impact of GLP-1 analogue treatment on the progression of coronary artery disease (expressed as a change in the % change in the volume of non-calcified atherosclerotic plaque in CT assessed by coronary CT) in relation to routine treatment (intention-to-treat);
The impact of GLP-1 analogue treatment on the progression of coronary artery disease (expressed as a change in the % change in the volume of non-calcified atherosclerotic plaque in CT assessed by coronary CT) in relation to routine treatment (intention-to-treat);
The impact of flozin treatment on the progression of coronary artery disease (expressed as a change in the % change in the volume of non-calcified atherosclerotic plaque at heart rate assessed in coronary CT) in relation to routine treatment (intention-to-treat);
The impact of flozin treatment on the progression of coronary artery disease (expressed as a change in the % change in the volume of non-calcified atherosclerotic plaque at heart rate assessed in coronary CT) in relation to routine treatment (intention-to-treat);
次要结局
- The effect of each of the tested drugs vs. the control group on the progression of coronary artery disease (expressed as a change in the % change in the volume of uncalcified atherosclerotic plaque in t.w. assessed in coronary CT) (as treated);
- Comparison of the effect of semaglutide vs. flozin on the progression of coronary artery disease (expressed as a change in the % change in the volume of uncalcified atherosclerotic plaque at heart rate assessed by coronary CT scan)(intention to treat/as treated);
- The effect of each of the tested drugs vs. the control group/comparison of the effect of semaglutide vs. flozin on the progression of coronary artery disease (expressed as a % change in the volume of the entire atherosclerotic plaque in t.w. assessed in coronary CT); (intention to treat/as treated)
- The effect of each of the tested drugs vs. the control group/comparison of the effect of semaglutide vs. flozin on the progression of coronary artery disease (expressed as a % change in the volume of individual components of the atherosclerotic plaque in CT assessed in coronary CT); (intention to treat/as treated);
- Assessment of the effect of each of the studied drugs vs. the control group/comparison of the effect of semaglutide vs. flozin on the progression of coronary artery disease (expressed as the conversion of non-calcified plaque into calcified plaque in CT assessed in coronary CT); (intention to treat/as treated);
- Assessment of the impact of individual tested drugs vs. the control group/comparison of the effect of semaglutide vs. flozin on the risk of SN expressed as the dynamics of high-risk features 1. Change in the number of high-risk atherosclerotic lesions defined as the presence of at least 2 high-risk features among: spotty calcifications, low attenuation plaque, i.e. plaque density < 30 HU, positive remodeling, napkin ring sign assessed in koro-CT 2. Change in Pericoronary FAI assessed in koro-CT
- Evaluation of weight change, including body composition, in patients treated with semaglutide vs. patients treated with flozin - weight - body mass index (BMI). - fat mass - skeletal muscle mass - Fat-To-Muscle Ratio (FMR). - Body Cell Mass (BCM) - Visceral Fat Area (VFA
- Evaluation of waist-to-hip index (WHI) change in patients treated with semaglutide vs. patients treated with phlorizin
- Evaluation of change in inflammatory parameters in patients treated with semaglutide vs. patients treated with phlorizin. Concentration of hsCRP
- Evaluation of change in lipid levels in patients treated with semaglutide vs. patients treated with flozin. - total cholesterol - low-density lipoproteins (LDL) - high-density lipoproteins (HDL) - non-HDL cholesterol - triglycerides - lipoprotein A
- Evaluation of change in the percentage of glycated hemoglobin (HBA1c) in patients treated with semaglutide vs. patients treated with flozin
- Evaluation of change in the percentage of patients with normal blood pressure in patients treated with semaglutide vs. patients treated with flozin. Change in percentage of patients with normal blood pressure defined as systolic pressure <140 mmHg and diastolic pressure <90 mmHg
- Change in the percentage of patients who smoke tobacco
- Evaluation of compliance with physical activity recommendations in patients treated with semaglutide vs. patients treated with flozin. - Percentage of patients classified in the "high" physical activity category; - Percentage of patients classified in the "sufficient" physical activity category; - Percentage of patients classified in the "insufficient" physical activity category
- Evaluation of dietary compliance in patients treated with semaglutide vs. patients treated with flozin. Change in the DASH Index between baseline and end of study
- Diagnosis of diabetes based on the criteria of the Polish Diabetes Association
- Evaluation of the onset of heart failure requiring hospitalization. Hospitalization for heart failure.
- Number of unplanned hospitalizations
- Number of major cardiovascular events and strokes (MACCE: death/myocardial infarction/revascularization/stroke) separately and combined.
- Homeostatic Model Change Assessment – Insulin Resistance (HOMA-IR).
- Assessment of changes in the concentration of selected oxidative stress markers.Change in concentration of selected oxidative stress markers: catalase, superoxide dismutase (SOD), Oxygen Radical Absorbance Capacity (ORAC), total antioxidant capacity (TAC)
研究者
Principal Investigator
Scientific
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityNCT07293325Second Affiliated Hospital, School of Medicine, Zhejiang University66
尚未招募
4 期
Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.2025-520802-37-00Universita' Degli Studi Di Napoli Federico II80
招募中
3 期
An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients (STABIL-NOR – study).2023-506109-20-00Helse Bergen HF140
招募中
4 期
The Impact of Semaglutide Compared to Energy Restriction on Type 2 DiabetesNCT07272343Second Affiliated Hospital of Nanchang University100
招募中
3 期
Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)NCT07295223Instituto Mexicano del Seguro Social44